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Is monotherapy maintenance the way forward?
Paton and colleagues1 report the results of a large 
randomised controlled trial assessing protease inhibitor 
monotherapy as a simpliﬁ cation strategy for long-term 
management of HIV infection. Of the 587 individuals 
with an HIV infection who were on suppressive combined 
antiretroviral therapy (ART) included in the study, most 
preserved all drug options after median follow-up of 
44 months. The choice of this original primary endpoint 
recognises the need for both patients and physicians 
to be conﬁ dent that protease inhibitor monotherapy 
does not jeopardise future treatment options.2 This 
trial provides a deﬁ nite response to the scepticism 
surrounding this speciﬁ c question. Although the authors 
aimed for a pragmatic trial in a real-life setting with 
treatment switches or protease inhibitor choices at 
clinicians’ discretion, frequent and careful virological 
monitoring with stringent criteria was used. In this 
context, the real-life setting is that in high-income and 
middle-income countries.
During the entire 3–5 year follow-up, 58% of eligible 
patients were able to stay on a monotherapy strategy, 
which is comparable with results noted in the most recent 
darunavir monotherapy trials.3,4 Because many patients 
cannot remain on the preplanned single-protease 
inhibitor strategy in the long run and careful monitoring 
is needed, does the clinical beneﬁ t of protease inhibitor 
monotherapy exceed these disadvantages? Few diﬀ er-
ences were noted between groups in serious adverse 
events, cardiovascular risk, quality of life, or renal disease; 
neuropsychological tests did not report a clinically 
relevant risk, contrary to ﬁ ndings in a smaller study,5 
which showed one case of cerebrospinal ﬂ uid escape in 
a cohort of patients given darunavir. Bone density was 
not reported, which is regrettable because the eﬀ ect of 
boosted protease inhibitors on bone remains a subject 
of debate.6,7 Absolute changes in lipid concentrations 
were also not reported, but the role of the combination 
of tenofovir and emtricitabine in reduction of total 
cholesterol has been suggested by ﬁ ndings from a 
randomised trial.8
11 years after the ﬁ rst boosted protease inhibitor 
monotherapy trial,9 repositioning of this strategy is 
critical. In the trial reported by Paton and colleagues, 
eligible patients had started on ART without profound 
immune suppression and were willing (and able) 
to be carefully monitored with frequent HIV RNA 
measurement. Thus, the patients included in this 
mono therapy maintenance trial might have been 
particularly worried about side eﬀ ects or might have 
already experienced nucleoside analogue reverse 
transciptase inhibitor-related toxicity. In view of the 
many ﬁ xed-dose combinations available for ﬁ rst-line 
treatment, maintenance does not necessarily mean 
fewer pills, but rather refers to drug sparing in the long 
term and perhaps cost savings.10 The coformulation of 
the new cobicistat booster, together with darunavir,11 
makes the strategy attractive for patients with a 
once-daily, one-pill maintenance regimen. 
In the absence of a short-term cure for HIV disease, 
a simpliﬁ ed maintenance regimen for patients on 
suppressive ART is a relevant strategy. However, many 
individuals remain excluded from access to a protease 
inhibitor-based single maintenance regimen, either 
because of suboptimum virological control or an 
absence of the necessary infrastructure to monitor 
such a regimen. Is a universal simpliﬁ ed maintenance 
regimen in sight? Other regimens are competing with 
a single-protease inhibitor strategy. Margolis and 
colleagues12 showed excellent antiviral activity in a 
phase 2 trial comparing cabotegravir plus rilpivirine vs 
efavirenz plus dual-nucleoside reverse transcriptase 
inhibitors until the end of week 96.
Industry-sponsored studies (NCT02263326 and 
NCT02527096) continue to compare use of dolutegravir, 
a potent integrase-strand inhibitor, together with 
lamivudine to provide a potentially low cost and easily 
coformulated dual combination for maintenance. Is 
integrase-strand inhibitor-based monotherapy a future 
possibility? Dolutegravir shows very good tolerability, 
high potency, and a distinctive resistance proﬁ le because 
of increased plasma concentrations and extended 
binding with the integrase–DNA complex.13 Findings 
from clinical trials suggest a high genetic barrier at 
least similar to that of boosted protease inhibitors. 
Dolutegravir-based maintenance treatment at the low 
dose of 50 mg given once daily without food constraint 
could possibly have a role as a safe, convenient, and 
aﬀ ordable maintenance regimen, thus providing 
reassurance that a generic drug will be available at low 
cost.14 Fully powered randomised controlled trials will 
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be needed to assess whether dolutegravir will need to 
be combined with another antiviral drug, or whether 
monotherapy will be an acceptable, eﬃ  cient, robust, and 
universal alternative to protease inhibitors. 
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